Valuing Post-Revenue Biopharmaceutical Assets with Pfizer's Current Portfolio as a Case Study
The research introduces a new model for predicting future sales of post-revenue biopharmaceutical assets, aiding more strategic investment decisions in the biotech and pharmaceutical sectors.
Featured in No. 28 on 6 Dec 2023 · 2 days after release · 0 citations today
- Released
- 4 Dec 2023
- First featured
- No. 28 · 6 Dec 2023
- Citations (Semantic Scholar)
- 0
- Influential citations
- 0
- Published in
- Not yet, as far as Semantic Scholar knows
- Shares when featured
- 5
- Identifier
- arXiv:2312.02250
Citations and venue from Semantic Scholar (ODC-BY), refreshed weekly. Summary: Quant Letter (CC BY 4.0).